160 related articles for article (PubMed ID: 36853323)
1. Mutational Damages in Malignant Lung Tumors.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Dushimova Z; Vasilieva T
Asian Pac J Cancer Prev; 2023 Feb; 24(2):709-716. PubMed ID: 36853323
[TBL] [Abstract][Full Text] [Related]
2. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
Chang YL; Wu CT; Shih JY; Lee YC
Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
[TBL] [Abstract][Full Text] [Related]
3. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X
Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833
[TBL] [Abstract][Full Text] [Related]
4. Characteristic Mutational Damages in Gastric and Colorectal Adenocarcinomas.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
[TBL] [Abstract][Full Text] [Related]
5. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
6. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
7. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
9. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
10. Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Ahmed ZA; Moatter T; Siddiqui A; Pervez S
Asian Pac J Cancer Prev; 2014; 15(17):7125-8. PubMed ID: 25227801
[TBL] [Abstract][Full Text] [Related]
11. Association of hOGG1-Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer.
Chen MJ; Shen CJ; Wang L; Chen PM; Chen CY; Lee H
Thorac Cancer; 2021 Feb; 12(4):534-538. PubMed ID: 33372419
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
Hoque MO; Brait M; Rosenbaum E; Poeta ML; Pal P; Begum S; Dasgupta S; Carvalho AL; Ahrendt SA; Westra WH; Sidransky D
J Thorac Oncol; 2010 Dec; 5(12):1887-93. PubMed ID: 21102258
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.
Sarkar FH; Li Y; Vallyathan V
Int J Mol Med; 2001 Oct; 8(4):453-9. PubMed ID: 11562787
[TBL] [Abstract][Full Text] [Related]
17. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
[TBL] [Abstract][Full Text] [Related]
18. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
19. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
20. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.
Miyamae Y; Shimizu K; Hirato J; Araki T; Tanaka K; Ogawa H; Kakegawa S; Sugano M; Nakano T; Mitani Y; Kaira K; Takeyoshi I
Oncol Rep; 2011 Apr; 25(4):921-8. PubMed ID: 21318227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
